Futura Medical Interim Results for the Six Months Ended 30 June 2011
Highlights
- Significant progress across the Company and in particular with two products, CSD500 and PET500
- PET500 – Worldwide rights licensed to Ansell Limited in February 2011 with launch expected 2012
- Placing in March 2011 raised £3.20 million (£3.07 million net of expenses), strengthening Futura’s balance sheet
- Net loss of £0.62 million (H1 2010: Net loss of £0.44 million)
- Cash resources of £3.40 million at 30 June 2011 (30 June 2010: £1.32 million)
Post Balance Sheet Events
- CSD500 – CE mark awarded in August 2011 clearing regulatory pathway for launch as a Durex® branded condom
James Barder, Futura’s Chief Executive, said: “The current year has started extremely well. We have signed a commercial deal with Ansell for PET500 and we were delighted to receive notification of the CE mark award to Reckitt Benckiser for CSD500 in early August. We are looking forward to the launch of the first of these products in early 2012.”
For any further information please contact:
Futura Medical plc
James Barder, Chief Executive
Tel: +44 (0)1483 685 670
mail to: james.barder@futuramedical.com
www.futuramedical.com
Nomura Code Securities Limited
Phil Walker / Giles Balleny
Tel:+44 (0)20 7776 1200
For media enquiries please contact:
Buchanan Communications
Mark Court / Jessica Fontaine Tel: +44 (0)20 7466 5000
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com